Otsu/Shiga Japan – December 2, 2013 – Takara Bio Inc. announced today the launch of several new research reagents relating to adeno-associate virus (AAV) vectors for gene transduction that will become available for sale on December 16, 2013 through Takara Bio’s sales network.

 

The most important feature of the AAV vectors that attracts gene therapy researchers is that the vectors were developed from adeno-associated viruses, which lack pathogenicity. In addition, the vectors are replication-defective parvoviruses that are capable of infecting a broad range of host cells, including non-dividing cells, and show high gene transduction efficiency. Because of their remarkable safety, AAV vectors have been used in gene therapy clinical trials for the treatment of several diseases such as hemophilia and Parkinson’s disease. In 2012, the first gene therapy drug in the western world, which was developed using an AAV vector, was approved in Europe.

 

Among the new products that Takara Bio launches is the “AAVpro® Helper Free System (AAV2)”, which increases virus production efficiency with miRNA sequences more than two-fold compared to other similar products available in the market.
The “AAVpro® Titration Kit (for Real Time PCR)” is the world’s first kit for calculating AAV titre by the (quantitative) Real Time PCR, enabling the rapid estimation of the number of vector genomes.

 

The Takara group focuses on developing new products based on gene transduction vectors in the fields of both gene therapy and genetic engineering research. As with the AAV pro® series, we will continue to expand research reagents related to AAV vectors.

 

[ About Takara Bio Inc. ]

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology including functional food and mushroom production businesses; and is committed preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com.